The recent rumor is McKesson is looking at Medline again. McKesson is pushing into Europe and China and Medline’s global sourcing is appealing. McKesson’s new CEO wants a larger global footprint and sees Medline as a low cost way of doing it. It would also allow McKesson to leverage the med-surg business to enter hospital IDN’s with a complete solution ultimately growing their pharmaceutical business and taking market share away from Cardinal.